Document is current

Article History

Received: 17 August 2024

Accepted: 22 January 2025

First Online: 7 February 2025

Declarations

:

: Dr. Kaneko has received speaker’s honoraria from Eisai, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, and Sumitomo Pharma. Dr. Furihata has received research grants from Nishikawa Foundation for Medical Promotion, and Terumo Life Science Foundation. Dr. Uchiyama has served as a medical consultant for Idorsia Pharmaceuticals Japan Ltd., Lixil Corporation, and Taisho Pharmaceutical Co., Ltd. Dr. Suzuki’s work was supported by JSPS KAKENHI (JP20K07956), Grants-in-Aid for Scientific Research, Ministry of Health, Labour and Welfare (19FA1009 and 21FA0201), and an Intramural Research Grant (2–1) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Suzuki has received payment for expert testimony, research grants, and speaker’s honoraria from Eisai and Mochida Pharmaceutical, research grants and speaker’s honoraria from EA Pharma, Meiji Seika Pharma, Mochida Pharmaceutical, Otsuka Pharmaceutical, Shionogi Pharma, and Sumitomo Pharma, payment for expert testimony from Jazz Pharmaceuticals and Kao Corporation, and speaker’s honoraria from Kyowa Pharmaceutical Industry, MSD, Takeda Pharmaceutical, Viatris, and Yoshitomi Pharmaceutical. All other authors report no financial relationships with any other commercial interests.